Showing results (1271-1280 of 1,512) with videos related to
Sort By:
Pageof 152
Kidney Research and Clinical Practice|February 7, 2023
Comparison of dominant and nondominant C3 deposition in primary glomerulonephritisJiwon Ryu, Eunji Baek, Hyung-Eun Son, et al.European Journal of Cancer (Oxford, England : 1990)|February 4, 2014
Randomised phase II trial of photodynamic therapy plus oral fluoropyrimidine, S-1, versus photodynamic therapy alone for unresectable hilar cholangiocarcinomaDo Hyun Park, Sang Soo Lee, So Eun Park, et al.Oncology Reports|October 20, 2004
A multi-center, late phase II clinical trial of Genexol (paclitaxel) and cisplatin for patients with advanced gastric cancerSook Ryun Park, Do-Youn Oh, Dong-Wan Kim, et al.Journal of Leukocyte Biology|October 21, 2006
Mechanisms underlying TGF-beta1-induced expression of VEGF and Flk-1 in mouse macrophages and their implications for angiogenesisSeong-Hyun Jeon, Byung-Chul Chae, Hyun-A Kim, et al.Investigational New Drugs|June 29, 2022
First-in-human phase 1/1b study to evaluate sitravatinib in patients with advanced solid tumorsTodd Bauer, Byong Chul Cho, Rebecca Heist, et al.Lung Cancer (Amsterdam, Netherlands)|January 13, 2026
Durvalumab-containing treatment for recurrent or metastatic pulmonary sarcomatoid carcinoma: A pooled post hoc analysis of two KCSG phase II trialsDong Hyun Kim, Miso Kim, Jeonghwan Youk, et al.Breast Cancer Research : BCR|March 4, 2011
Ki-67 can be used for further classification of triple negative breast cancer into two subtypes with different response and prognosisBhumsuk Keam, Seock-Ah Im, Kyung-Hun Lee, et al.Oncology|January 23, 2009
Efficacy and safety of S-1 monotherapy in patients with advanced biliary tract adenocarcinoma: retrospective analysis of 162 patientsInkeun Park, Jae-Lyun Lee, Min-Hee Ryu, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|May 4, 2020
An International Real-World Analysis of the Efficacy and Safety of Lorlatinib Through Early or Expanded Access Programs in Patients With Tyrosine Kinase Inhibitor-Refractory ALK-Positive or ROS1-Positive NSCLCViola W Zhu, Yen-Ting Lin, Dong-Wan Kim, et al.Journal of Thoracic Oncology : Official Publication of the International Association for the Study of Lung Cancer|February 4, 2019
Health-Related Quality of Life in KEYNOTE-010: a Phase II/III Study of Pembrolizumab Versus Docetaxel in Patients With Previously Treated Advanced, Programmed Death Ligand 1-Expressing NSCLCFabrice Barlesi, Edward B Garon, Dong-Wan Kim, et al.Pageof 152